Secukinumab is a fully human monoclonal antibody that targets interleukin-17A (IL-17A), a proinflammatory cytokine implicated in multiple immune-mediated inflammatory diseases. It is used in the clinical management of conditions such as plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and uveitis. IL-17A is part of a broader family of cytokines elevated in chronic inflammation and autoimmune disorders, making it a critical therapeutic target. By neutralizing IL-17A, secukinumab helps restore immune balance, reduce inflammation, and improve disease symptoms, particularly in dermatological and rheumatologic conditions.
In clinical settings, secukinumab has demonstrated substantial efficacy in patients with moderate-to-severe plaque psoriasis by normalizing skin histology. Approved by the FDA in 2015, it is administered via subcutaneous injection and has become a first-line biologic treatment option for several IL-17–mediated diseases. As a biologic drug, therapeutic drug monitoring (TDM) is recommended to assess individual pharmacokinetics and optimize dosing, especially in cases of poor response or suspected non-compliance.
In research, secukinumab serves as a tool for understanding the role of IL-17A in autoimmune pathophysiology and for developing new strategies to manage inflammatory disease. Given its potential to provoke anti-drug antibodies (ADAs), immune profiling and biosimilar development are key areas of study. Its success has paved the way for broader IL-17–targeted therapies and highlighted the value of personalized biologic treatments in autoimmune care
This product is manufactured in Turkey by Matriks Biotek.